Marinos G, Torre F, Günther S, Thomas M G, Will H, Williams R, Naoumov N V
Institute of Liver Studies, King's College School of Medicine and Dentistry, London, England.
Gastroenterology. 1996 Jul;111(1):183-92. doi: 10.1053/gast.1996.v111.pm8698197.
BACKGROUND & AIMS: Genomic variants of the hepatitis B virus (HBV) with core gene deletions have been identified in patients with chronic active hepatitis B, but the significance of these mutations in the course of chronic HBV infection remains unknown. The aim of this study was to longitudinally analyze the changes of HBV core gene deletion variants under the enhanced immune pressure of interferon alfa treatment and hepatitis B e antigen (HBeAg) to antibody to hepatitis B e antigen (anti-HBe) seroconversion.
HBV precore/core gene was amplified in 358 serum samples from 67 chronic HBV carriers (all HBeAg-positive) followed up for a period of 2-11 years. The core gene deletions were analyzed by gel electrophoresis, cloning, and DNA sequencing.
HBV mutants with core gene deletions (37-250 base pairs) were detected in patients with long-standing HBV replication and ongoing hepatic inflammation, always together with the wild-type strain. They were associated with a significantly lower level of viremia and a high rate of seroconversion to anti-HBe. Core gene deletion mutants were preferentially eliminated after seroconversion, in contrast to the accumulation of HBV strains with a precore stop codon.
These data indicate that HBV variants with core gene deletions may inhibit HBV replication, do not persist in preference of the wild-type HBV under enhanced immune pressure, and do not confer resistance to interferon alfa treatment.
在慢性活动性乙型肝炎患者中已鉴定出具有核心基因缺失的乙型肝炎病毒(HBV)基因组变异体,但这些突变在慢性HBV感染过程中的意义仍不清楚。本研究的目的是纵向分析在干扰素α治疗和乙肝e抗原(HBeAg)向乙肝e抗体(抗-HBe)血清学转换的增强免疫压力下HBV核心基因缺失变异体的变化。
对67例慢性HBV携带者(均为HBeAg阳性)随访2至11年的358份血清样本中的HBV前核心/核心基因进行扩增。通过凝胶电泳、克隆和DNA测序分析核心基因缺失情况。
在长期HBV复制和持续肝脏炎症的患者中检测到具有核心基因缺失(37至250个碱基对)的HBV突变体,且总是与野生型毒株同时存在。它们与病毒血症水平显著降低和抗-HBe血清学转换率高有关。与具有前核心终止密码子的HBV毒株积累相反,核心基因缺失突变体在血清学转换后优先被清除。
这些数据表明,具有核心基因缺失的HBV变异体可能抑制HBV复制,在增强免疫压力下不会优先于野生型HBV持续存在,并且不会赋予对干扰素α治疗的抗性。